Amgen, Allergan launch cancer biosimilars in the US: 4 things to know

Amgen and Allergan have launched their biosimilar competitors to two of Roche's top-selling cancer drugs in the U.S., according to PharmaPhorum.

Four things to know:

1. The companies said that the initial list price for the two drugs will be 15 percent lower than the price of their reference product.  

2. Amgen launched Mvasi, a biosimilar to Avastin. It will be available at a wholesale cost of $677.4 per 100 milligrams  and $2,709.60 for a single-dose vial. 

3. Allergan has launched Kanjiti, a biosimilar to Herceptin. It will be available at $3,697.26 per 420-milligram vial.

4. Herceptin and Avastin together brought in sales of $5.8 billion in 2018 for Roche.

Read the full report here

More articles on pharmacy:
Oklahoma opioid trial wraps: 10 takeaways
Drugmaker tried to shred records before FDA inspection, agency claims
Publix Pharmacy to deliver prescriptions to patients before hospital discharge

Copyright © 2024 Becker's Healthcare. All Rights Reserved. Privacy Policy. Cookie Policy. Linking and Reprinting Policy.


Featured Whitepapers

Featured Webinars